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Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic
blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-
transplantation lymphoproliferative disorder (PTLD) in the ﬁrst year after transplantation. We evaluated
the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as
GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD
prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD
prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients
(67%). No cases of PTLD occurred during the ﬁrst year after allo-BMT in this series. PTLD is a rare occurrence
after allo-BMT using PTCy, even in high-risk alternative donor transplantations.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION HLA-haploidentical donors, and umbilical cord blood (UCB),
The approach to graft-versus-host disease (GVHD)
prophylaxis, including methods of graft manipulation and
pharmacologic immunosuppression, affects immune recon-
stitution after allogeneic blood or marrow transplantation
(allo-BMT) and modulates the risk for post-transplantation
lymphoproliferative disorder (PTLD). The risk of PTLD peaks
in the early months after allo-BMT, and the vast majority
of cases occur within the ﬁrst year after transplantation
[1]. PTLD lesions that arise after allo-BMT typically harbor
Epstein-Barr virus (EBV).
A multi-institutional analysis of PTLD incidence among
26,901 allo-BMTs performed at 271 institutions worldwide
found that selective T cell depletion of grafts and, to a lesser
extent, other approaches to lymphocyte depletion were
associated with increased risk for PTLD [1]. Patients who
receive antithymocyte globulin (ATG) as GVHD prophylaxis
also are considered at higher risk for PTLD [1,2]. The use of
alternative donors, including unrelated donors (URDs),edgments on page 1516.
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heightened risk seems related mainly to the intensiﬁed
GVHD prophylaxis strategies often used with alternative
donor grafts. The incidence of PTLD in patients receiving URD
or haploidentical grafts accompanied by ATG and/or selective
T cell depletion is 4% to 8% [1]. The incidence of PTLD after
UCB allo-BMT is 2% to 7%, but rates up to 17% have been re-
ported with UCB allo-BMT using ATG [2-5].
The use of post-transplantation cyclophosphamide
(PTCy) as GVHD prophylaxis after allo-BMT is associatedwith
comparatively low rates of severe acute and chronic GVHD,
even with the use of URD and haploidentical grafts [6].
However, given that approaches that are highly effective in
preventing GVHD may be associated with higher rates of
PTLD, we evaluated the incidence of PTLD associated with
PTCy at the Johns Hopkins Hospital (JHH).MATERIALS AND METHODS
Once JHH Institutional Review Board approval was obtained, the JHH
Transplant Research databases were queried for patients age 18 years who
received PTCy as GVHD prophylaxis at JHH between January 1, 2000, and
December 31, 2011. Clinical notes, pathology reports, and radiology reports
up through the ﬁrst year after allo-BMT were reviewed.
For myeloablative conditioning, patients received a regimen of busulfan
(Bu) and cyclophosphamide (Cy) as described previously [7]. Reduced-
intensity conditioning (RIC) regimens were ﬂudarabine (Flu)-based, with
the majority (n ¼ 354) consisting of Flu/Cy/total body irradiation (TBI) [8].
Table 1
Patient and Transplant Characteristics (n ¼ 785)
Characteristic Value
Age, yr, median (range) 52 (18-75)
Male, n (%) 448 (57)
Diagnosis, n (%)
AML or myelodysplastic syndrome 308 (39)
Mature B cell neoplasm 236 (30)
Acute lymphoblastic leukemia 69 (9)
Myeloproliferative neoplasm, including CML 52 (7)
Hodgkin’s lymphoma 48 (6)
Mature T cell or natural killer cell neoplasm 36 (5)
Hemoglobinopathy or thalassemia 17 (2)
Aplastic anemia or paroxysmal nocturnal
hemoglobinuria
9 (1)
Bilineage leukemia 7 (1)
Histiocytic or dendritic cell neoplasm 2
Lymphomatoid granulomatosis 1
Conditioning regimen, n (%)
Reduced-intensity 456 (58)
Myeloablative 329 (42)
ATG-containing conditioning regimen, n (%) 14 (2)
Donor, n (%)
HLA-haploidentical* 396 (50)
HLA-matched related 259 (33)
HLA-matched or 1 antigen-mismatched unrelated 130 (17)
Allograft source, n (%)
Marrow, T cell replete 748 (95)
Peripheral blood, T cell replete 37 (5)
GVHD prophylaxis, n (%)
PTCy alone 313 (40)
PTCy on days þ3 and þ4 302
PTCy on day þ3 11
PTCy on days þ3 and þ4/MMF/tacrolimusy 382 (49)
PTCy on days þ3 and þ4/MMFz 55 (7)
PTCy on day þ3/MMF/tacrolimusx 20 (2)
PTCy on days þ3 and þ4/MMF/sirolimusk 15 (2)
Rituximab 12 months after allo-BMT, n (%) 63 (8)
HLA-haploidentical 55/396 (14)
HLA-matched related 8/259 (3)
HLA-matched or 1 antigen-mismatched unrelated 0/130
DLI 12 months after allo-BMT, n (%) 57 (7)
HLA-haploidentical 13/396 (3)
HLA-matched related 41/259 (16)
HLA-matched or 1 antigen-mismatched unrelated 3/130 (2)
CML indicates chronic myelogenous leukemia; MMF, mycophenolate
mofetil.
* Total of 395 related donors and 1 unrelated donor.
y MMF 15 mg/kg 3 times daily up to 1000 mg/dose on days 5-35 and
tacrolimus (goal trough, 5-15 ng/mL) on days 5-180. Twenty patients
received MMF 15 mg/kg twice daily on days 4-33.
z MMF 15 mg/kg twice daily on days 4-33.
x MMF 15 mg/kg twice daily on days 4-35 and tacrolimus (goal trough,
5-15 ng/mL) on days 4-50 (n ¼ 10) or days 4-180 (n ¼ 10).
k MMF 15 mg/kg 3 times daily up to 1000 mg/dose on days 5-35 and
sirolimus daily (goal trough, 5-15 ng/mL) on days 5-365.
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(n ¼ 14) [9], and alemtuzumab/Flu/TBI (n ¼ 2). All grafts were T cell replete.
When used as sole GVHD prophylaxis, PTCy 50 mg/kg/day was given i.v.
on days þ3 and þ4 after allo-BMT [7] in all but 11 patients, who received
PTCy on day þ3 only. Most recipients of haploidentical grafts and/or RIC
received additional immunosuppression after PTCy on days þ3 and þ4 after
allo-BMT, with the majority receiving mycophenolate mofetil and tacroli-
mus. GVHD prophylaxis regimens are shown in Table 1.
PTLD was deﬁned using the 2008 World Health Organization classiﬁ-
cation scheme [10]. Data on the use of posteallo-BMT therapies that could
modulate PTLD risk, including donor lymphocyte infusion (DLI) and ritux-
imab therapy, were compiled. Death was considered a competing risk for
PTLD. R version 2.15.2 (R Core Development Team, Vienna, Austria) was used
to estimate the cumulative incidence of death.Figure 1. Cumulative incidence of death by allograft type. At 1 year, the
cumulative incidence of death was similar for recipients of HLA-haploidentical,
unrelated, and HLA-matched related donor allografts at 34% (95% CI, 29% to
38%), 30% (95% CI, 22 to 38%), and 29% (95% CI, 23% to 34%), respectively. The
cumulative incidence of PTLD is not shown, given the absence of events.RESULTS
Between 2000 and 2011, a total of 785 allo-BMTs were
performed at JHH, with PTCy administered as GVHD
prophylaxis (Table 1). PTCy was used as the sole GVHDprophylaxis in 313 of these allo-BMTs (40%), 295 of which
involved myeloablative conditioning and HLA-matched
grafts. Haploidentical or URD grafts were used in 526 (67%)
of the allo-BMTs overall.
Almost all patients (n¼ 762; 97%) had sufﬁcient follow-up
to assess for PTLD in the year after allo-BMT,with 505patients
followed for at least 1 year by JHH physicians, 203 surviving
less than 1 year but followed until death or hospice enroll-
ment, and 54 resuming carewith an outside oncologist before
1 year posteallo-BMT but corresponding with JHH when
clinical issues arose. The cumulative incidence of death at
1 year was 34% (95% conﬁdence interval [CI], 29% to 38%) for
recipients of haploidentical allo-BMT, 30% (95%CI, 22% to 38%)
for recipients of URD allo-BMT, and 29% (95% CI, 23% to 34%)
for recipients of matched related donor allo-BMT (Figure 1).
No cases of PTLDwere identiﬁed among the 762 patientswith
adequate follow-up. Twenty-three patients had insufﬁcient
follow-up to assess for PTLD through 1 year posteallo-BMT,
but no cases of PTLD were identiﬁed during the available
follow-up in these patients (median, 3.7months; range,1.6 to
11.9 months).
DLI, adoptive EBV-speciﬁc cellular immunotherapy, and
rituximab therapy have proven effective in treating PTLD. In
our cohort, 57 patients received DLI within the year after
allo-BMT, but in no case was DLI given for suspected or
conﬁrmed PTLD. Adoptive immunotherapy with EBV-speciﬁc
cytotoxic T lymphocytes was not used in this cohort. Sixty-
three patients received rituximab during the year after
allo-BMT, including 43 patients with CD20þ lymphoma who
received 8 weekly doses of rituximab on engraftment after
RIC allo-BMT (41 haploidentical and 2 HLA-matched related
donor grafts) as part of a clinical protocol, 19 patients who
received rituximab as part of treatment for relapsed
B-lineage malignancy, and 1 patient who received 1 dose of
preemptive rituximab for a modest, asymptomatic elevation
of EBV DNA copy number in the blood at 4 months after allo-
BMT at an outside institution, in keeping with that institu-
tion’s protocol for posteallo-BMT EBV monitoring. That
patient’s elevated EBV DNA copy number was not associated
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other clinical ﬁndings of concern for PTLD. EBV DNA moni-
toring was continued, and viral DNA was intermittently
detected, but the patient remained without signs or symp-
toms of EBV-associated disease and was healthy at nearly
3 years after allo-BMT.
DISCUSSION
The absence of PTLD after allo-BMT using PTCy is note-
worthy, particularly given that no routine EBV monitoring
was performed. Many transplantation centers perform EBV
monitoring and administer rituximab preemptively in an
attempt to decrease the risk for PTLD after allo-BMT,
particularly in high-risk patients [3,5,11-13]. Because graft
elutriation was used at JHH before the implementation of
PTCy-based approaches and the associated rate of PTLD was
very low [14,15], monitoring EBV DNA in the blood after
allo-BMT has not been an institutional standard [16].
Considering that EBV DNA is commonly detected in the
blood after allo-BMT, with wide variations in copy number
among patients and in individual patients over time,
elevated EBV DNA in the blood after low-risk allo-BMT
should be interpreted with caution [17,18]. In asymptomatic
patients, even sustained elevations of EBV DNA in the blood
after allo-BMT lack speciﬁcity for predicting the develop-
ment of PTLD [18].
In reports from other centers that use PTCy as prophy-
laxis, in a collective total of 162 allo-BMTs with PTCy, no
cases of PTLD were reported [19-24]. Of these 162 allo-BMTs,
63 were performed at centers that monitor EBV [20,24]. One
center reported that only 1 of the 13 patients who under-
went allo-BMT with PTCy developed elevated EBV-DNA in
the blood and no patients developed PTLD, compared with
a 12% incidence of PTLD with other approaches [24]. Another
center reported elevated EBV-DNA in the blood in 4 of 50
recipients of allo-BMT with PTCy, 1 of whom was found to
have EBV gastritis [20,25]. The data are limited, and inter-
pretation of EBV-DNA copy number in the blood after allo-
BMT with PTCy remains uncharted territory.
The absence of PTLD in the year after allo-BMT in our
series suggests that effective GVHD prophylaxis need not be
associated with an increase in PTLD. Our institution and
others have reported the effectiveness of PTCy as GVHD
prophylaxis in patients receiving HLA-matched related,
HLA-matched URD, or haploidentical grafts, with the
cumulative incidence of grade III-IV acute GVHD ranging
from 6% to 12% [6-8,20,21,23]. Thus, it appears that the
prevention of PTLD with PTCy does not come at the cost of
higher GVHD rates.
In considering death as a competing risk for PTLD, a large
majority of patients in this series survived for at least 1 year
after allo-BMT, including patients at elevated risk for PTLD
(i.e., recipients of haploidentical or URD grafts). Furthermore,
the vast majority were alive in the ﬁrst 6 months after allo-
BMT, when the risk for PTLD is highest. Given that this
series includes hundreds of patients who survived for longer
than 1 year and thus remained at risk for PTLD, it seems
unlikely that early deaths would completely account for the
absence of PTLD in this series.
Several hypotheses might be considered to explain the
lack of PTLD with PTCy prophylaxis, including destruction of
donor and host EBV-infected B cells, relative sparing of EBV-
speciﬁc memory T cells, and rapid immune reconstitution.
Investigations into thesemechanisms, including EBV-speciﬁc
T cell recovery after allo-BMT using PTCy, are ongoing.Regardless of the cause, PTCy is associated with very low to
absent rates of PTLD after allo-BMT, even with the use of
unrelated or HLA-mismatched donors.ACKNOWLEDGMENTS
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G-CSFa b s t r a c t
Analyses of healthy donors of granulocyte colony-stimulating factor (G-CSF) mobilized hematopoietic stem and
progenitor cells (HSPCs) and of patients undergoing autologous stem cell transplantation have suggested that
individuals harboring the CXCL12-A allele mobilize a higher number of CD34 þ HSPCs after G-CSF adminis-
tration. We typed 463 healthy unrelated donors (376 men and 87 women) who had received daily subcuta-
neous injections at a mean dose of 7.36  1.71 mg/kg G-CSF for 5 days for CXCL12 801 G/A using a real-time PCR
assay. Interestingly, the median concentration of mobilized CD34 þ cells on day 5 was almost identical in
donors with the A-allele (79/mL; range,11 to 249/mL) and the G/G-group (82/mL; range,15 to 268/mL). In addition,
the allelic distribution was not different in donors (n ¼ 11) who mobilized less than 20/mL CD34 þ cells. No
difference in the overall yield of CD34 þ cells in the apheresis product and in the number of CD34 þ cells/kg
recipient could be detected between both groups. In a multivariate regression model for the endpoint
CD34þ cells/mL at day 5, only male sex (regression coefﬁcient, 11.5; 95% conﬁdence interval, 1.7 to 21.2, P¼ .021)
and body mass index as continuous variables (regression coefﬁcient, 3.5; 95% conﬁdence interval, 2.5 to 4.5,
P ¼ .0001) but not age, smoking status, or CXCL12 allelic status represented independent variables. Our data
derived from a large well-controlled cohort contradict previous analyses suggesting an association between
CXCL12 allelic status and the yield of CD34 þ HSPC after G-CSF mobilization. Concentration of CD34 þ cells in
the peripheral blood, the most objective parameter, could not be predicted by CXCL12 genotype.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Peripheral blood stem cells (PBSCs) collected after mobi-
lization with granulocyte colony-stimulating factor (G-CSF)
are themost frequently applied source of hematopoietic stem
and progenitor cells (HSPCs) for allogeneic transplantation.
This preference is mainly due to a faster engraftment of
neutrophils and platelets and to a less invasive procedure not
requiring in-hospital stays or general anesthesia [1].
In approximately 75% of donors, one single leukapheresis
is sufﬁcient to collect the CD34þ cell dose required, whereas
